C-105 Clinical trial of HER2 cancer vaccine shows benefit in 45% of evaluable patients in phase I study

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES(2019)

引用 0|浏览21
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要